Qualcomm Announces Quarterly Cash Dividend
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.85 per common share, payable on June 20, 2024, to stockholders of record at the close of business on May 30, 2024.
About Qualcomm
Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Our proven solutions drive transformation across major industries, and our Snapdragon® branded platforms power extraordinary consumer experiences. Building on our nearly 40-year leadership in setting industry standards and creating era-defining technology breakthroughs, we deliver leading edge AI, high-performance, low-power computing, and unrivaled connectivity. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress.
Qualcomm Incorporated includes our licensing business, QTL, and the vast majority of our patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of our engineering and research and development functions and substantially all of our products and services businesses, including our QCT semiconductor business. Snapdragon and Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated. For more information, visit www.qualcomm.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417546476/en/
Contact information
Qualcomm Contact:
Mauricio Lopez-Hodoyan, Investor Relations
Phone: 1-858-658-4813
Email: ir@qualcomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology30.4.2024 14:31:00 EEST | Press release
TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries. This agreement with Lonza strengthens TriLink’s objective to drive greater access to CleanCap® mRNA capping technologies as the demand for mRNA – a promising therapeutic modality – continues to grow. According to the terms of the agreement, TriLink® will supply its patented CleanCap® M6, CleanCap® AG 3’OMe, CleanCap® AG, and CleanCap® AU cap analogs for use in Lonza’s global mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap® technology is a one-pot solution with over 95% capping efficiency that streamlines mRNA production processes when compared to legacy capping methods. “CleanCap® technology is accelerating programs from discovery to
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition30.4.2024 14:05:00 EEST | Press release
Debiopharm ( www.debiopharm.com ), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, and Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced that the first patient has been dosed in Module 4 of the ongoing Phase 1/1b MYTHIC (NCT04855656) clinical trial, investigating the combination of Debio 0123 and lunresertib. In this trial, Debiopharm and Repare seek to assess the safety, pharmacokinetics, pharmacodynamics and preliminary clinical activity of this PKMYT1 and WEE1 inhibitor combination. In early January, Debiopharm and Repare announced a collaboration to evaluate the clinical combination of Debio 0123, an oral, brain-penetrant, highly selective WEE1 kinase inhibitor and lunresertib, a first-in-class, selective and potent oral small molecule inhibitor of PKMYT1. This collaboration is based on preclinical in vivo data and other
General Mills Advances Accelerate Strategy and Expands Pet Food Portfolio with Acquisition of Edgard & Cooper30.4.2024 14:00:00 EEST | Press release
General Mills (NYSE: GIS) today announced it has completed the acquisition of Edgard & Cooper, one of Europe’s leading independent premium pet food brands. With this transaction, the company further advances its Accelerate strategy, including the prioritization of its core markets, global platforms and local gem brands to drive sustainable, profitable growth and top-tier shareholder returns over the long term. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429809015/en/ General Mills today announced it has completed the acquisition of Edgard & Cooper, one of Europe’s leading independent premium pet food brands. Established in 2016, Edgard & Cooper is one of the fastest-growing and most-recognized independent pet food companies in Europe, with estimated 2023 retail sales of more than €100 million across 13 markets. With this transaction, General Mills further advances its Accelerate strategy, including the prioritization o
Sustainability Regulation Propelling Transformation in Corporate Reporting, According to New Survey by Workiva30.4.2024 13:00:00 EEST | Press release
The majority (81%) of companies not subject to the European Union’s Corporate Sustainability Reporting Directive (CSRD) intend to partially or fully align their sustainability disclosures with its requirements, according to an independent survey commissioned by Workiva Inc. (NYSE:WK). The third annual 2024 ESG Practitioner Survey polled more than 2,000 people involved in corporate reporting, including finance and accounting, sustainability, risk, and internal audit professionals across North America, Europe, and Asia. “The adoption of the CSRD was a pivotal moment, marking the first major regulation calling for integrated financial and sustainability disclosures with third-party assurance. Now, as companies around the world gear up for their first mandated CSRD reports in 2025, we’re seeing CSRD’s impact extend far beyond those subject to the regulation,” said Paul Volpe, Senior Vice President of Growth Solutions at Workiva. “The CSRD has initiated a global shift toward assured integra
Horizon3.ai Unveils Rapid Response Service for Cyber Resilience30.4.2024 13:00:00 EEST | Press release
Horizon3.ai, a pioneer in autonomous security solutions, today announced the launch of its Rapid Response service, now part of the NodeZero™ platform. This one-of-a-kind capability marks a significant advancement in autonomous penetration testing solutions by addressing a critical gap in measuring the real-world impact of exploitable vulnerabilities within the software many organizations have come to rely on. Now, organizations can gain a clear understanding of their ‘likelihood of exploitability’ for the most critical vulnerabilities being announced. As organizations continue to contend with both zero-day and N-day vulnerabilities, the window of time between the public disclosure of a vulnerability and threat actors exploiting them in the wild is steadily shrinking. Knowing this predicament, organizations spend vast amounts of time, money, and resources patching the software they use after hearing of a vendor vulnerability announcement. Yet, how often are organizations expending consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom